FY2017 Earnings Estimate for Exelixis, Inc. Issued By Leerink Swann (EXEL)
Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Leerink Swann raised their FY2017 earnings per share estimates for Exelixis in a report released on Friday. Leerink Swann analyst M. Schmidt now anticipates that the biotechnology company will earn $0.45 per share for the year, up from their prior estimate of $0.44. Leerink Swann has a “Market Perform” rating and a $28.00 price target on the stock. Leerink Swann also issued estimates for Exelixis’ Q1 2018 earnings at $0.11 EPS, Q2 2018 earnings at $0.15 EPS, Q3 2018 earnings at $0.16 EPS, Q4 2018 earnings at $0.21 EPS and FY2020 earnings at $1.77 EPS.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The business had revenue of $152.50 million during the quarter, compared to the consensus estimate of $104.91 million. During the same period in the prior year, the company earned ($0.04) EPS. Exelixis’s revenue for the quarter was up 145.2% on a year-over-year basis.
Shares of Exelixis (NASDAQ:EXEL) opened at $30.01 on Monday. Exelixis has a 1 year low of $16.72 and a 1 year high of $32.50. The firm has a market capitalization of $8,880.00, a price-to-earnings ratio of 61.24, a P/E/G ratio of 0.95 and a beta of 1.88.
A number of institutional investors have recently bought and sold shares of EXEL. Vanguard Group Inc. raised its position in Exelixis by 7.2% in the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock valued at $626,635,000 after purchasing an additional 1,706,893 shares during the last quarter. Matrix Capital Management Company LP raised its position in Exelixis by 8.8% in the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after purchasing an additional 1,225,000 shares during the last quarter. Janus Henderson Group PLC bought a new position in Exelixis in the second quarter valued at about $28,689,000. Macquarie Group Ltd. raised its position in Exelixis by 811.5% in the third quarter. Macquarie Group Ltd. now owns 1,276,453 shares of the biotechnology company’s stock valued at $30,928,000 after purchasing an additional 1,136,409 shares during the last quarter. Finally, First Trust Advisors LP raised its position in Exelixis by 588.9% in the third quarter. First Trust Advisors LP now owns 1,086,135 shares of the biotechnology company’s stock valued at $26,317,000 after purchasing an additional 928,475 shares during the last quarter. Hedge funds and other institutional investors own 81.15% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.